My research is based on improving outcomes for patients with chemoresistant cancers. I am chief investigator of the national adjuvant melanoma phase 3 trial, collaborating with Mark Middleton, Oxford, who leads associated translational studies focusing on angiogenesis predictive and prognostic biomarkers. Locally, am collaborating with Ultan McDermott, studying gene sequencing in melanoma tissue taken from patients receing molecular targeted therapies, to identify molecular response and resistance mechanisms. I work with Duncan Jodrell and Bristi Basu in the pancreatic experimental therapeutics programme.